133 related articles for article (PubMed ID: 2626745)
1. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.
Telgt DS; Macik BG; McCord DM; Monroe DM; Roberts HR
Thromb Res; 1989 Dec; 56(5):603-9. PubMed ID: 2626745
[TBL] [Abstract][Full Text] [Related]
2. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
3. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats.
Diness V; Lund-Hansen T; Hedner U
Thromb Res; 1990 Sep; 59(6):921-9. PubMed ID: 2264019
[TBL] [Abstract][Full Text] [Related]
4. Activity and regulation of glycoPEGylated factor VIIa analogs.
Ghosh S; Sen P; Pendurthi UR; Rao LV
J Thromb Haemost; 2008 Sep; 6(9):1525-33. PubMed ID: 18624982
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
6. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
7. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.
Darlington DN; Delgado AV; Kheirabadi BS; Fedyk CG; Scherer MR; Pusateri AE; Wade CE; Cap AP; Holcomb JB; Dubick MA
J Trauma; 2011 Nov; 71(5):1152-63. PubMed ID: 21610535
[TBL] [Abstract][Full Text] [Related]
8. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
[TBL] [Abstract][Full Text] [Related]
9. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
10. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Welsch DJ; Novotny WF; Wun TC
Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
[TBL] [Abstract][Full Text] [Related]
11. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa.
Rao LV; Rapaport SI
Blood; 1990 Mar; 75(5):1069-73. PubMed ID: 2306514
[TBL] [Abstract][Full Text] [Related]
12. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
13. Do PT and APTT sensitivities to factors' deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?
Martinuzzo M; Barrera L; Rodriguez M; D'Adamo MA; López MS; Otaso JC
Int J Lab Hematol; 2015 Dec; 37(6):853-60. PubMed ID: 26338156
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
Hedner U; Ljundberg J; Lund-Hansen T
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):145-51. PubMed ID: 2130926
[TBL] [Abstract][Full Text] [Related]
15. Protein disulfide isomerase has no stimulatory chaperone effect on factor X activation by factor VIIa-soluble tissue factor.
Persson E
Thromb Res; 2008; 123(1):171-6. PubMed ID: 18550154
[TBL] [Abstract][Full Text] [Related]
16. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
[TBL] [Abstract][Full Text] [Related]
17. Coagulation Testing in the Core Laboratory.
Winter WE; Flax SD; Harris NS
Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
[TBL] [Abstract][Full Text] [Related]
18. Plasma-derived factors VIIa and X mixtures (Byclot
Ochi S; Takeyama M; Shima M; Nogami K
Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Weeterings C; Lisman T; de Groot PG
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.
Bijsterveld NR; Vink R; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
Br J Haematol; 2004 Mar; 124(5):653-8. PubMed ID: 14871253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
